NASDAQ:OPGNOpGen Stock Price, Forecast & News

OpGen's stock was trading at $2.07 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, OPGN shares have increased by 0.0% and is now trading at $2.07. View which stocks have been most impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OpGen in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for OpGen.

OpGen is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for OpGen.

OpGen Inc (NASDAQ:OPGN) announced its quarterly earnings data on Thursday, May, 7th. The medical research company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.39) by $0.14. The medical research company had revenue of $0.62 million for the quarter. OpGen had a negative return on equity of 241.40% and a negative net margin of 405.10%. View OpGen's earnings history.

OpGen shares reverse split on Friday, January 19th 2018. The 1-25 reverse split was announced on Wednesday, January 17th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 18th 2018. An investor that had 100 shares of OpGen stock prior to the reverse split would have 4 shares after the split.

OpGen updated its first quarter 2020 Pre-Market earnings guidance on Tuesday, April, 14th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $617K - 617K, compared to the consensus revenue estimate of $800K.

2 brokers have issued 12 month target prices for OpGen's stock. Their forecasts range from $5.00 to $20.00. On average, they anticipate OpGen's stock price to reach $12.50 in the next year. This suggests a possible upside of 503.9% from the stock's current price. View analysts' price targets for OpGen.

Press coverage about OPGN stock has trended negative on Monday, according to InfoTrie Sentiment. The research group ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. OpGen earned a news impact score of -2.1 on InfoTrie's scale. They also assigned news articles about the medical research company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news about OpGen.

OpGen saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 974,300 shares, an increase of 13.1% from the June 15th total of 861,500 shares. Based on an average trading volume of 1,070,000 shares, the short-interest ratio is presently 0.9 days. Approximately 6.5% of the shares of the company are short sold. View OpGen's Current Options Chain.

Some companies that are related to OpGen include Enzo Biochem (ENZ), Biocept (BIOC), Celcuity (CELC), Anpac Bio-Medical Science (ANPC), Miragen Therapeutics (MGEN), Psychemedics (PMD), Avant Diagnostics (AVDX), CBA Florida (CBAI), PotNetwork (POTN), Cancer Genetics (CGIX), First Choice Healthcare Solutions (FCHS) and Aeon Global Health (AGHC). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other OpGen investors own include Anavex Life Sciences (AVXL), Agile Therapeutics (AGRX), Energy Transfer LP Unit (ET), Protalix Biotherapeutics (PLX), Inovio Pharmaceuticals (INO), vTv Therapeutics (VTVT), Vaxart (VXRT), Crispr Therapeutics (CRSP), SCYNEXIS (SCYX) and Sorrento Therapeutics (SRNE).

(OPGN) raised $17 million in an IPO on Tuesday, May 5th 2015. The company issued 2,900,000 shares at $5.50-$6.50 per share. Maxim Group served as the underwriter for the IPO and National Securities was co-manager.

OpGen trades on the NASDAQ under the ticker symbol "OPGN."

Shares of OPGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of OPGN stock can currently be purchased for approximately $2.07.

OpGen has a market capitalization of $31.19 million and generates $3.50 million in revenue each year. The medical research company earns $-12,450,000.00 in net income (profit) each year or ($6.90) on an earnings per share basis. OpGen employs 44 workers across the globe.

The official website for OpGen is www.opgen.com.

OpGen's mailing address is 708 QUINCE ORCHARD ROAD SUITE 205, GAITHERSBURG MD, 20878. The medical research company can be reached via phone at 240-813-1260 or via email at [email protected]